SCHEMBL6420869

SCHEMBL6420869

COC(=O)c1nscc1C=CC=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 5/20 0.33
STAT3 P40763 1/20 0.33
HIF1A Q16665 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
MAPT P10636 4/20 0.32
ALDH1A1 P00352 3/20 0.32
TDP1 Q9NUW8 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
NPC1 O15118 4/20 0.30
RAB9A P51151 4/20 0.30
XDH P47989 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
KMT2A Q03164 1/20 0.30
KDM4C Q9H3R0 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420865 1.00 NPSR1 (0.38) NPSR1KDM4ESTAT3HIF1ACDK4
SCHEMBL6425899 0.79 NPSR1 (0.37) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL6425897 0.79 NPSR1 (0.37) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL6421448 0.72 KDM4E (0.33) KDM4ECDK4CCND1MAPTALDH1A1
SCHEMBL6421451 0.72 KDM4E (0.33) KDM4ECDK4CCND1MAPTALDH1A1
SCHEMBL12263255 0.72 NPSR1 (0.46) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL109707 0.72 NPSR1 (0.46) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL31319640 0.72 NPSR1 (0.46) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL6422368 0.70 NPSR1 (0.45) NPSR1KDM4ESTAT3HIF1AMAPT
SCHEMBL27912113 0.70 NPSR1 (0.45) NPSR1KDM4ESTAT3HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 NPSR1 3205/4885KDM4E 2031/4885STAT3 108/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 NPSR1 2172/4885KDM4E 430/4885STAT3 102/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 NPSR1 2160/4885KDM4E 477/4885STAT3 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.